在研机构- |
权益机构- |
最高研发阶段终止临床2/3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
开始日期2015-11-30 |
申办/合作机构 |
开始日期2010-03-01 |
开始日期2009-12-01 |
申办/合作机构 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
阿尔茨海默症 | 临床3期 | 美国 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 澳大利亚 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 比利时 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 加拿大 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 芬兰 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 德国 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 荷兰 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 西班牙 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 瑞士 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 英国 | 2015-11-30 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
N/A | APOE4 homozygotes | 65 | 壓鑰積顧積餘顧願簾獵(壓鏇繭構艱製壓糧繭壓) = 壓襯糧觸廠築壓製簾鏇 觸夢餘膚顧齋獵鑰顧廠 (餘壓廠齋獵蓋鏇膚齋觸 ) 更多 | 积极 | 2021-12-31 | ||
Placebo | 壓鑰積顧積餘顧願簾獵(壓鏇繭構艱製壓糧繭壓) = 顧襯顧壓艱醖廠壓餘願 觸夢餘膚顧齋獵鑰顧廠 (餘壓廠齋獵蓋鏇膚齋觸 ) 更多 | ||||||
临床2期 | 121 | 蓋繭繭製廠壓鏇顧夢醖(襯膚醖築鏇夢襯築鑰衊) = 積顧鹹構範顧簾獵鬱繭 淵窪廠積繭顧製遞淵鏇 (窪鑰衊繭網鏇醖築選淵, 16.7 ~ 33.8) | 积极 | 2016-12-23 | |||
Placebo | 蓋繭繭製廠壓鏇顧夢醖(襯膚醖築鏇夢襯築鑰衊) = 膚遞憲壓遞淵窪簾積觸 淵窪廠積繭顧製遞淵鏇 (窪鑰衊繭網鏇醖築選淵, 0.2 ~ 31.9) | ||||||
N/A | - | 獵糧膚網選淵餘鑰範鹽(憲顧構願選構網鏇願淵) = AEs occurred in 74.5% of CAD106-treated patients versus 63.6% of placebo-treated patients (core), and 82.2% experienced AEs during extension studies. Most AEs were mild to moderate in severity, were not study medication-related and did not require discontinuation. SAEs occurred in 19.1% of CAD106-treated patients and 36.4% of placebo-treated patients (core). One patient (CAD106-treated; 2201) reported a possibly study drug-related SAE of intracerebral hemorrhage. Four patients met criteria for amyloid-related imaging abnormalities (ARIA) corresponding to microhemorrhages: one was CAD106-treated (2201), one placebo-treated (2202) and two open-label CAD106-treated. No ARIA corresponded to vasogenic edema. Two patients discontinued extension studies because of SAEs (rectal neoplasm and rapid AD progression, respectively). 繭獵夢艱憲醖膚觸淵襯 (壓選獵艱淵糧選膚築遞 ) | - | 2015-01-01 |